MX2017003015A - Metodo para tratar canceres solidos y/o metastasis de los mismos, medicamentos para los mismos, y metodo para predecir el resultado clinico para tratar canceres solidos y/o metastasis de los mismos. - Google Patents

Metodo para tratar canceres solidos y/o metastasis de los mismos, medicamentos para los mismos, y metodo para predecir el resultado clinico para tratar canceres solidos y/o metastasis de los mismos.

Info

Publication number
MX2017003015A
MX2017003015A MX2017003015A MX2017003015A MX2017003015A MX 2017003015 A MX2017003015 A MX 2017003015A MX 2017003015 A MX2017003015 A MX 2017003015A MX 2017003015 A MX2017003015 A MX 2017003015A MX 2017003015 A MX2017003015 A MX 2017003015A
Authority
MX
Mexico
Prior art keywords
metastases
solid cancers
treating solid
predicting
medicaments
Prior art date
Application number
MX2017003015A
Other languages
English (en)
Inventor
Staub Eike
Straub Josef
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2017003015A publication Critical patent/MX2017003015A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención proporciona un nuevo método para tratar cáncer colorectal (CRC) y metástasis del mismo en sujetos, y de manera preferente también de otros cánceres sólidos y metástasis de los mismos en sujetos, en donde el método depende de manera preferente en si el paciente muestra ciertos niveles de proteínas específicos en uno o más fluidos corporales antes de o durante el tratamiento, en donde el tratamiento comprende la administración de al menos uno inhibidor de integrina pan a? a un paciente, un medicamento para el uso en los nuevos métodos y un método para predecir el resultado de un tratamiento con al menos un inhibidor de integrina pan a? basado en los niveles de proteínas específicos en uno o más fluidos corporales del paciente.
MX2017003015A 2014-09-17 2015-08-18 Metodo para tratar canceres solidos y/o metastasis de los mismos, medicamentos para los mismos, y metodo para predecir el resultado clinico para tratar canceres solidos y/o metastasis de los mismos. MX2017003015A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462051530P 2014-09-17 2014-09-17
PCT/EP2015/001699 WO2016041614A1 (en) 2014-09-17 2015-08-18 A method of treating solid cancers and/or metastases thereof, medicaments therefore, and a method of predicting the clinical outcome of treating solid cancers and/or metastases thereof

Publications (1)

Publication Number Publication Date
MX2017003015A true MX2017003015A (es) 2017-05-23

Family

ID=53969334

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017003015A MX2017003015A (es) 2014-09-17 2015-08-18 Metodo para tratar canceres solidos y/o metastasis de los mismos, medicamentos para los mismos, y metodo para predecir el resultado clinico para tratar canceres solidos y/o metastasis de los mismos.

Country Status (14)

Country Link
US (2) US11415581B2 (es)
EP (1) EP3193927B1 (es)
JP (2) JP7372025B2 (es)
KR (1) KR20170052690A (es)
CN (1) CN107073111A (es)
AU (2) AU2015317409A1 (es)
BR (1) BR112017005336A2 (es)
CA (1) CA2961421C (es)
ES (1) ES2856348T3 (es)
IL (1) IL251078B (es)
MX (1) MX2017003015A (es)
RU (1) RU2017112998A (es)
SG (1) SG11201702135PA (es)
WO (1) WO2016041614A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2897782T3 (es) 2014-09-17 2022-03-02 Merck Patent Gmbh Método de tratamiento de las enfermedades de la metástasis ósea, medicamentos para el tratamiento y método para predecir el resultado clínico del tratamiento de las enfermedades causadas por metástasis ósea
CN108957014A (zh) * 2018-09-27 2018-12-07 郑州大学第附属医院 结直肠癌血清标志物、表达评估方法、试剂盒及应用
EP3867276A1 (en) * 2018-10-19 2021-08-25 Merck Patent GmbH Abituzumab for the treatment of colorectal cancer

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2082160C (en) 1991-03-06 2003-05-06 Mary M. Bendig Humanised and chimeric monoclonal antibodies
DK0719859T3 (da) 1994-12-20 2003-10-20 Merck Patent Gmbh Anti-alfa V-integrin monoklonalt antistof
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
EP1418897A2 (en) 2001-05-02 2004-05-19 Novartis AG Use of bisphosphonates in the treatment of bone metastasis associated with prostate cancer
JP2004002321A (ja) 2002-03-11 2004-01-08 Takeda Chem Ind Ltd 性ホルモン依存性疾患治療剤
US20050159361A1 (en) 2002-03-11 2005-07-21 Takahito Hara Remedies for sex hormone-dependent disease
AU2004227018A1 (en) 2003-04-08 2004-10-21 Colotech A/S A method for detection of colorectal cancer in human samples
WO2007084670A2 (en) 2006-01-18 2007-07-26 Merck Patent Gmbh Specific therapy using integrin ligands for treating cancer
WO2007103116A2 (en) * 2006-03-02 2007-09-13 Laboratory Corporation Of America Holdings Methods and systems for evaluating health risk factors by measurement of dna damage and dna repair
PL2167128T3 (pl) 2007-07-17 2013-03-29 Merck Patent Gmbh Skonstruowane metodami inżynierii hybrydowe przeciwciała skierowane przeciwko integrynie alfa-v
JP5403534B2 (ja) 2008-10-29 2014-01-29 インフォコム株式会社 食道癌の予後予測のための情報を提供する方法
CA2746120A1 (en) * 2008-12-23 2010-07-01 Genentech, Inc. Methods and compositions for diagnostic use in cancer patients
EA020764B1 (ru) 2008-12-23 2015-01-30 Мерк Патент Гмбх Биомаркеры для ингибиторов с антиангиогенной активностью
US20120039805A1 (en) * 2009-02-20 2012-02-16 Pangea Biosciences, Inc. Therapeutics And Methods For Treating Neoplastic Diseases Comprising Determining The Level Of Caveolin-1 And/Or Caveolin-2 In A Stromal Cell Sample
ES2661238T3 (es) 2009-06-19 2018-03-28 Merck Patent Gmbh Biomarcadores y métodos para determinar la eficacia de anticuerpos anti-EGFR en la terapia del cáncer
ES2530732T3 (es) 2009-09-17 2015-03-05 Hoffmann La Roche Procedimientos de diagnóstico para el cáncer de pulmón
EP2606349A4 (en) * 2010-08-20 2014-04-30 Univ Jefferson AGENTS FOR CANCER DIAGNOSIS AND CANCER THERAPY
SI2672994T1 (sl) 2011-02-11 2018-09-28 Merck Patent Gmbh Protitelo proti alfa-v integrinu za zdravljenje raka prostate
MX340453B (es) 2011-05-25 2016-07-08 Novartis Ag Biomarcadores para cancer de pulmon.
WO2012167028A2 (en) * 2011-06-02 2012-12-06 The Regents Of The University Of California Compositions and methods for treating cancer and diseases and conditions responsive to cell growth inhibition
JP6335875B2 (ja) 2012-03-30 2018-05-30 ジェネンテック， インコーポレイテッド 癌の治療のための診断法及び組成物
WO2013152313A1 (en) * 2012-04-05 2013-10-10 The Regents Of The University Of California Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
ES2897782T3 (es) 2014-09-17 2022-03-02 Merck Patent Gmbh Método de tratamiento de las enfermedades de la metástasis ósea, medicamentos para el tratamiento y método para predecir el resultado clínico del tratamiento de las enfermedades causadas por metástasis ósea

Also Published As

Publication number Publication date
CA2961421C (en) 2024-01-30
JP2017535516A (ja) 2017-11-30
KR20170052690A (ko) 2017-05-12
RU2017112998A3 (es) 2019-03-28
JP7372025B2 (ja) 2023-10-31
EP3193927B1 (en) 2020-11-25
CA2961421A1 (en) 2016-03-24
US11415581B2 (en) 2022-08-16
CN107073111A (zh) 2017-08-18
AU2015317409A1 (en) 2017-04-27
AU2021203352A1 (en) 2021-06-24
RU2017112998A (ru) 2018-10-17
ES2856348T3 (es) 2021-09-27
IL251078B (en) 2021-05-31
JP7242617B2 (ja) 2023-03-20
IL251078A0 (en) 2017-04-30
JP2021009154A (ja) 2021-01-28
EP3193927A1 (en) 2017-07-26
US20170298134A1 (en) 2017-10-19
US20220334117A1 (en) 2022-10-20
BR112017005336A2 (pt) 2017-12-12
WO2016041614A1 (en) 2016-03-24
SG11201702135PA (en) 2017-04-27

Similar Documents

Publication Publication Date Title
MX2023002251A (es) Antagonistas de union al eje pd-l1 y usos de los mismos para el tratamiento de cancer.
MX2020008882A (es) Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
MX2019011117A (es) Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
CY1122143T1 (el) Φαρμακευτικοι συνδυασμοι που περιλαμβανουν εναν αναστολεα της b-raf, εναν αναστολεα του egfr και προαιρετικα εναν αναστολεα της ρι3κ-αλφα
MX2022008868A (es) Tratamiento del cancer con tg02.
MX2017003406A (es) Metodo para tratar enfermedades de metastasis osea, medicamentos para las mismas, y metodo para predecir el resultado clinico para tratar enfermedades de metastasis osea.
MX2020011783A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
PH12015501744B1 (en) Therapeutic and diagnostic target for cancer comprising dll3 binding reagents
MX2021010672A (es) Uso de un anticuerpo que tiene la capacidad para ligarse a clnd6 en el tratamiento o prevención de cáncer.
MX2019011148A (es) Metodos de tratamiento.
MX2022008266A (es) Metodos para el almacenamiento de sangre completa y composiciones de esta.
BR112014027905A2 (pt) anticorpo, célula, ácido nucleico, métodos de identificação de um primeiro anticorpo, de inibição do crescimento de uma célula, de tratamento terapêutico, de determinação da presença de uma proteína, de diagnóstico da presença de um tumor e de distribuição de agente citotóxico.
MX2017003513A (es) Formación de imágenes de inflamación e infección dirigida a hsp90 y terapia.
EP4252742A3 (en) Fluticasone furoate in the treatment of copd
MY176219A (en) Combination therapy for cancer
MX2018009499A (es) Anticuerpos monoclonales especificos de egfl6 y metodos de su uso.
MX2017003015A (es) Metodo para tratar canceres solidos y/o metastasis de los mismos, medicamentos para los mismos, y metodo para predecir el resultado clinico para tratar canceres solidos y/o metastasis de los mismos.
MX2018011025A (es) Metodos para tratar o prevenir la enfermedad del injerto contra huésped.
EP3552014A4 (en) INCOMPATIBLE BLOOD GROUP ANTIGEN FOR CANCER DETECTION AND TREATMENT
WO2015144184A8 (en) Use of timp-1 as a biomarker in the egf-receptor inhibitor treatment of metastatic colorectal cancer
WO2019053116A8 (en) Method for guidance of fluid therapy based on proadrenomedullin
UA106224U (uk) Спосіб прогнозування зрощення перелому
UA107731U (uk) Спосіб прогнозування зрощення перелому
UA104420U (uk) Спосіб прогнозування зрощення перелому